Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01635426|
Recruitment Status : Unknown
Verified March 2017 by Mohamed Ellaithy, Ain Shams University.
Recruitment status was: Recruiting
First Posted : July 9, 2012
Last Update Posted : March 10, 2017
The study will compare the effect of Aspirin versus clopidogrel effect on uterine perfusion in women with unexplained recurrent pregnancy loss with decreased uterine artery pulsatility index.
Null hypothesis: Women with recurrent miscarriage have the same blood flow after aspirin or clopidogrel treatment compared to their uterine artery pulsatility index before treatment.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Pregnancy Loss||Drug: Aspirin Drug: Clopidogrel||Phase 2 Phase 3|
Hide Detailed Description
Recurrent miscarriage has been associated with genetic, anatomic, endocrine, immunologic, behavioral, environmental factors and prothrombotic states; however, almost 50% of cases of recurrent miscarriage are unexplained.
Angiogenesis and uterine blood supply are essential for both endometrial growth and embryo development. As a result, endometrial vascularity has been considered to play a critical role in endometrial receptivity formation and pregnancy maintenance. The development of three-dimensional (3D) ultra-sonography with power Doppler angiography provides an objective and reproducible way to determine endometrial-subendometrial vascularity , which may evaluate quantitatively the uterine vascularity microenvironment for the developing embryo.
Few studies have shown the application of 3D-power Doppler angiography in assessment of pregnancy loss.
The rationale behind the use of aspirin is that this substance, at low doses, produces a vasodilatatory effect by shifting the TXA2/PGI2 ratio toward the dominance of PGI2 activity through the inhibition of TXA2 production. TXA2 is synthesized mainly by platelets and induces platelet aggregation and vasoconstriction, whereas PGI2, produced at the level of vascular endothelial cells, inhibits platelet aggregation and promotes vasodilatation. Aspirin, at low doses, has been proven to produce the selective inhibition of TXA2 production. In fact, TXA2 is primarily produced by the activity of cyclooxygenase prostaglandin synthase-1 (COX-1) at the platelet level, which is highly sensitive to aspirin inhibition. In contrast, PGI2 is mainly synthesized in the endothelial cells through the activity of both COX-1 and COX-2, which is insensitive to aspirin administration at low doses. Therefore, the administration of aspirin at low doses reduces TXA2 production without affecting PGI2 secretion. It is reasonable that the increased PGI2 vasodilatation activity can enhance uterine perfusion, thereby improving reproductive outcome. In addition, it has been hypothesized that aspirin administration can reduce TXA2 endometrial cell excretion. It is known that TXA2 levels at the site of embryo implantation are crucial for the success of pregnancy. The presence of lower endometrial cell TXA2 production has been demonstrated in patients who became pregnant with respect to those who did not achieve pregnancy. For these reasons, low dose Aspirin supplementation is currently considered as an effective and safe treatment option in the prevention of several pregnancy complications.
Nevertheless, aspirin even when administered at low doses can cause gastrointestinal bleeding, as reported in studies using 30-50 mg daily. In addition, it has not been proved that enteric-coated or buffered aspirin is less likely to cause gastrointestinal bleeding than normal aspirin.
The search for active anti-platelet drugs within the original chemical class of the thienopyridines, led to the discovery of clopidogrel, a novel ADP-selective agent whose anti-aggregating properties are several times higher than those of ticlopidine. The anti-aggregating properties of this compound are well known and, very recently, new results have clarified its mechanism of action.
Clopidogrel is active only after intravenous or oral administration, and no circulating activity has been found in the plasma of treated animals or human volunteers.
Experiments in rats have demonstrated that the anti-aggregating activity was caused by a short lasting metabolite generated in the liver by a cytochrome P450-dependent pathway. The anti-aggregating property of clopidogrel is caused by an inhibition of the binding of ADP to its platelet receptors, and more specifically to the low affinity receptors, the high affinity binding sites being unaffected by clopidogrel. Several events in the ADP activation process, including adenylyl cyclase down-regulation, protein tyrosine phosphorylation, activation of the GPIIb-IIIa complex, fibrinogen binding, aggregation and release, were inhibited by clopidogrel and indicate their close relationship with the activation of a low affinity receptor by ADP. Thus, clopidogrel is not only a potent antithrombotic drug in humans but also a good tool to study the effect of ADP on platelets.
The purpose of this study is to compare the effect of Aspirin versus clopidogrel effect on uterine perfusion in women with unexplained recurrent pregnancy loss with decreased uterine artery pulsatility index.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||March 2018|
|Active Comparator: Aspirin||
Aspirin 75 mg daily for 2 months after meals
Other Name: Acetylsalicylic Acid
|Active Comparator: Clopidogrel||
Clopidogrel 75 mg daily for 2 months after meals
Other Name: Plavix
- Improvement in uterine artery pulsatility index [ Time Frame: 2 months ]
- Improvement in subendometrial blood flow [ Time Frame: 2 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01635426
|Contact: Mostafa I. Ibrahem, M.D.||firstname.lastname@example.org|
|Ain Shams University||Recruiting|
|Abbasiya, Cairo, Egypt, 11566|
|Contact: Mohamed I. Ellaithy, M.D. 00201006873417 email@example.com|
|Principal Investigator:||Mohamed I Ellaithy, M.D.||Ain Shams University|